Search Results
Your search for ,ARE matches 21644 pages
Showing 4851 - 4900Kerryn Reding, PhD, MPH, RN, Daughter of Health-Care Workers, Chooses a Career in Breast Cancer Survivorship
Kerryn Reding, PhD, MPH, RN—whose research focuses on reducing cancer incidence and improving survival, with particular interests in lifestyle interventions and biomarkers of risk—was born in Australia, but her family moved to Iowa when she was a toddler. “Both of my parents were in health care. My ...
President Biden Reignites Cancer Moonshot
As Vice President, in 2016, Joe Biden launched the Cancer Moonshot with the mission to accelerate the rate of progress against cancer. The cancer and patient community and medical researchers responded with energy and ingenuity. On February 2, President Biden announced the reigniting of the Cancer ...
ASCO and American Cancer Society Announce Collaboration to Empower People With Cancer Information They Can Trust
ASCO and the American Cancer Society (ACS) today initiated a collaboration to ensure that people can easily find the trusted, expert-approved cancer content they need when turning to either organization for information. As an initial step, the organizations are cross-sharing select cancer...
Challenges for Oncologists as They Reach Retirement Age
In 2014, The ASCO Post spoke with Mark J. Clemons, MB BS, BMedSci, MSc, MD, FRCP, FRCPC, of Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada, about the retirement challenges faced by many oncologists. With market demand expected to exceed supply of oncologists soon, it is clear retirement is...
Study Examines Head and Neck Cancer Incidence in Black Populations Around the World
Researchers have found that disparities in the incidence of head and neck cancer are driven by behavioral and environmental risk factors rather than race. They demonstrated this in the first-ever study to compare head and neck cancer incidence in Black patients in the United States, the Caribbean,...
FDA Approves Second COVID-19 Vaccine
On January 31, the U.S. Food and Drug Administration (FDA) approved a second COVID-19 vaccine, which has been known as the Moderna COVID-19 vaccine, for the prevention of COVID-19 in individuals aged 18 years and older; the approved vaccine will be marketed as Spikevax. “The FDA’s approval of [the...
Trastuzumab, Pertuzumab, and Docetaxel for Advanced HER2-Mutant NSCLC
In a French phase II trial (IFCT-1703-R2D2) reported in the Journal of Clinical Oncology, Julien Mazieres, MD, PhD, and colleagues found that the combination of trastuzumab, pertuzumab, and docetaxel produced durable responses in previously treated patients with advanced HER2-mutant non–small cell...
Assessing Value in Gastrointestinal Cancer Treatments
The era of precision oncology, in which molecular biomarkers are used to help guide drug delivery, has dovetailed with the emerging issues of value-based care and cost containment. To shed light on these issues and more, The ASCO Post spoke with Hanna K. Sanoff, MD, MPH, Clinical Medical Director...
New Study Examines Role of Genetic Ancestry in Pediatric Leukemia
Scientists at St. Jude Children’s Research Hospital are studying the impact of genetic ancestry on childhood acute lymphoblastic leukemia (ALL). The scientists assembled an international cohort to determine how genetic ancestry affects leukemia biology and outcomes for modern therapy; they found...
Genetic and Lifestyle Calculator May Help to Identify Younger Adults at Risk of Colorectal Cancer
A new risk score may aid in identifying men and women younger than 50 who are most likely to develop a cancer of the colon or rectum, an international study published by Archaumbault et al in the Journal of the National Cancer Institute showed. More About Scoring The score—a number between 0 and...
Use of Cancer Registry and Credit Records Data to Assess Risk of Adverse Financial Events in Patients With Cancer
In a population-based cohort study reported in the Journal of Clinical Oncology, Veena Shankaran, MD, MS, and colleagues found that patients with cancer were at a significantly increased risk of past-due credit card payments and other adverse financial events vs matched noncancer controls. As...
Gabriel A. Brooks, MPH, MD, on Colorectal Cancer: Expert Perspective on the Need to Deintensify Oxaliplatin
Gabriel A. Brooks, MPH, MD, of the Norris Cotton Cancer Center, discusses key studies that, when synthesized, suggest the benefits of oxaliplatin may be less than often assumed. The toxicities are well described (especially neuropathy), and the agent should be used cautiously and sparingly beyond...
Study Finds That Compared to Urban Residents, Rural Residents Are More Likely to Have Fatalistic Beliefs About Cancer
There is strong evidence showing that avoiding tobacco use, maintaining a healthy diet and weight, and being physically active are effective strategies for reducing cancer risk. In addition, the early detection of certain cancer types through screening has the potential to reduce cancer mortality...
MONALEESA Analyses Show Widespread Benefit for Ribociclib in Hormone Receptor–Positive, HER2-Negative Breast Cancer
Further analyses of the MONALEESA metastatic breast cancer trials have shown that the benefit of ribociclib plus endocrine therapy in the first-line setting extends to most intrinsic molecular subtypes and is consistent across multiple subgroups. The studies were presented at the 2021 San Antonio...
Young Adults May Have the Greatest Risk of Distant-Stage Colorectal Cancer, With the Highest Risk Among Black and Hispanic Patients
Colorectal cancer is the second most common cause of death in the United States. In 2020, approximately 148,000 people were diagnosed with the disease, and 53,200 people died from it, including 17,930 cases and 3,640 deaths in individuals younger than age 50. According to the American Cancer...
Risk of Multiple Cancers in Male Carriers of BRCA1 and BRCA2 Gene Mutations
People who carry the BRCA1 or BRCA2 gene mutation have an increased risk of pancreatic, stomach, and prostate cancers, as well as the previously well-known risk of breast and ovarian cancers, according to new research calling for increased testing in male carriers to detect the cancers early. The...
Effect of ADT Use and Duration in Combination With Definitive Radiotherapy for Localized Prostate Cancer
In an individual patient-level meta-analysis reported in The Lancet Oncology, Amar U. Kishan, MD, and colleagues found that the addition of androgen-deprivation therapy (ADT) to definitive radiotherapy prolonged metastasis-free and overall survival in patients with localized prostate cancer. Longer ...
Addition of Perioperative Trastuzumab to Neoadjuvant Chemoradiation for Patients With HER2-Overexpressing Esophageal Adenocarcinoma
As reported in The Lancet Oncology by Howard P. Safran, MD, and colleagues, the phase III NRG Oncology/RTOG-101 trial has shown no significant disease-free survival benefit with the addition of perioperative trastuzumab to neoadjuvant chemoradiation in previously untreated patients with...
Carolyn Presley, MD, on Dementia in Patients Treated for Thoracic Cancer
Carolyn Presley, MD, of The Ohio State University, discusses the differences between “chemo brain,” cognitive aging, and dementia in patients with thoracic cancer who are in treatment; how to test for impairment; and the interventions that can improve cognitive changes in survivors.
Study Identifies Black Race as Risk Factor for Lymphedema After Axillary Dissection in Women With Breast Cancer
Black women with breast cancer had significantly higher rates of lymphedema after axillary lymph node dissection compared with Hispanic, White, and Asian women in a prospective study of breast cancer–related lymphedema presented at the 2021 San Antonio Breast Cancer Symposium (SABCS). In fact,...
Lenvatinib/Pembrolizumab vs Chemotherapy in Previously Treated Patients With Advanced Endometrial Cancer
As reported in The New England Journal of Medicine by Vicky Makker, MD, and colleagues, the phase III Study 309-KEYNOTE-775 trial has shown prolonged progression-free and overall survival with lenvatinib plus pembrolizumab vs physician’s choice of chemotherapy among previously treated patients with ...
Cancer Biologist Beatrice Mintz, PhD, FAACR, Dies at 100
The American Association for Cancer Research (AACR) issued the following statement regarding the passing of Beatrice Mintz, PhD, FAACR, a trailblazing pioneer in multiple fields of cancer biology, who died January 3, 2022, at the age of 100. Born on January 24, 1921, in New York, New York, Dr....
Cancer Has Made Me a Risk-Taker, and That’s Good
In 2017, I was caring for my brother, who was suffering from respiratory failure due to complications from cerebral palsy, and working full-time as a registered nurse. I was feeling overwhelmed and exhausted all the time. I was also losing weight at an alarming rate—more than 70 pounds in just a...
A Guide for Patients With Breast Cancer, Their Families, and Their Oncologists
Writing a comprehensive book about breast cancer that is also concise and highly readable is no easy task. However, the authors of The Breast Cancer Book: A Trusted Guide for You and Your Loved Ones have done that and more by deftly communicating science and medical content for the lay public....
Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Burundi
The ASCO Post is pleased to continue this occasional special focus on the worldwide cancer burden. In this issue, we feature a close look at the cancer incidence and mortality rates in Burundi. The aim of this special feature is to highlight the global cancer burden for various countries of the...
An Adventurous Spirit Led to a Prominent Role in Radiation Oncology for Geraldine Jacobson, MD, MPH, MBA, FACR, FASTRO
Geraldine Jacobson, MD, MPH, MBA, FACR, FASTRO, founding Chair of the West Virginia University (WVU) Department of Radiation Oncology, was born in Fort Dix, New Jersey. Her father was a military officer, and his various duty posts offered an adventurous childhood for Dr. Jacobson. “One of my...
From the Vietnam War to the Stanford Cancer Institute: The Professional Journey of Quynh-Thu Le, MD
In this installment of the Living a Full Life series, guest editor, Jame Abraham, MD, FACP, spoke with Quynh-Thu Le, MD, Chair of the Department of Radiation Oncology and Co-Director of the Radiation Biology Program of the Stanford Cancer Institute, and one of the Group Chairs of the NRG Oncology...
Project Catalyst: Educating Industry to Help Develop Successful Cancer Therapies
OCE Insights is written by members of the Oncology Center of Excellence (OCE) and the Office of Oncology Diseases (OOD) at the U.S. Food and Drug Administration. In this installment, Jeff Summers, MD, OOD Acting Associate Director for Translational Sciences, and Marc R. Theoret, MD, OCE Deputy...
Pembrolizumab for Adjuvant Treatment of Stage IIB or IIC Melanoma
On December 3, 2021, pembrolizumab was approved for adjuvant treatment of adult and pediatric (≥ 12 years of age) patients with stage IIB or IIC melanoma following complete resection.1 Supporting Efficacy Data Approval was based on findings in the phase III, double-blind KEYNOTE-716 trial...
Daratumumab/Hyaluronidase-fihj and Carfilzomib in Multiple Myeloma
On November 30, 2021, daratumumab/hyaluronidase-fihj and carfilzomib were approved for use in combination with dexamethasone for adults with relapsed or refractory multiple myeloma who had one to three prior lines of therapy.1,2 Supporting Efficacy Data Approval was based on findings in a cohort...
Rituximab Plus Chemotherapy for Pediatric Mature B-Cell Non-Hodgkin Lymphoma and Mature B-Cell Acute Leukemia
On December 2, 2021, rituximab was approved for use in combination with chemotherapy for pediatric patients (≥ 6 months to 18 years) with previously untreated, advanced-stage, CD20-positive diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, or mature B-cell acute leukemia.1...
Roswell Park Receives Nearly $1 Million to Address Race-Related Disparities in Prostate Cancer
African American men currently have the highest rates of prostate cancer in the United States and the poorest outcomes. New grants from the U.S. Department of Defense and American Cancer Society will fund work by two Roswell Park Comprehensive Cancer Center teams focused on understanding and...
Adjuvant Atezolizumab in IMpower010: Moving the Needle in Early-Stage NSCLC
Adjuvant platinum-based chemotherapy for early-stage non–small cell lung cancer (NSCLC) is currently almost an afterthought and is taken for granted as a standard of care for patients with stage II to IIIA NSCLC after resection. The earliest meta-analysis, published in 1995,1 gave the first hint of ...
Promise and Need for More Progress in Treatment of Squamous Cell NSCLC
A greater understanding of the mutational landscape in non–small cell lung cancer (NSCLC) has identified key oncogenes, such as EGFR, ALK, ROS, RET, and BRAF, among others. These discoveries, coupled with the availability of specific targeted small-molecule inhibitors, have transformed the...
ASCO Statement on 50th Anniversary of Signing of National Cancer Act
“Fifty years ago, just a few days before the new year, former President Richard Nixon signed into law the National Cancer Act (NCA), setting a clear national priority to conquer cancer. “At the time the bill was signed into law, pioneers in our field had already made substantial discoveries, but we ...
ASCO Unveils New Equity, Diversity, and Inclusion Action Plan
Building on its long history of advancing health equity in cancer care, ASCO recently released “The ASCO Equity, Diversity, and Inclusion (EDI) Action Plan: A Legacy of Commitment, A Future of Promise for Individuals with Cancer.” The plan aims to infuse equity into all of the organization’s...
Health Groups Make Recommendations to Strengthen the U.S. Drug Supply Chain During the Pandemic and Beyond
ASCO—along with the American Medical Association, the American Society of Anesthesiologists, the American Society of Health-System Pharmacists, and the United States Pharmacopeia—released a series of policy and marketplace recommendations to address the significant challenges in our nation’s drug...
Pembrolizumab Plus Chemotherapy in Advanced Esophageal Cancer: Good News for Some, but More Work to Be Done
Multiple comparisons of traditional cytotoxic chemotherapy combinations that began decades ago led to the adoption of the platinum plus fluorouracil doublet as the standard of care for treatment of recurrent or metastatic esophageal cancer.1 Other combinations created by the addition and/or...
Expert Point of View: Jane N. Winter, MD
Jane N. Winter, MD, moderator of the press conference on late-breaking abstracts at the 2021 American Society of Hematology (ASH) Annual Meeting & Exhibition, commented on the BELINDA study in the context of two investigations that had been previously reported at the same meeting, showing...
BELINDA Trial: CAR T-Cell Therapy Fails to Improve Outcomes in Aggressive Non-Hodgkin Lymphoma
The autologous chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel failed to improve event-free survival vs standard-of-care treatment strategies in patients with aggressive, relapsed or refractory non-Hodgkin lymphoma (NHL), according to results of the phase III BELINDA trial,...
Expert Point of View: Laura C. Michaelis, MD
The moderator of the press briefing on COVID-19 in patients with blood disorders, held during the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition, was Laura C. Michaelis, MD, a clinician and clinical researcher at the Medical College of Wisconsin, Milwaukee. Dr. Michaelis...
Circadian Timing of Immune Checkpoint Inhibitors: Beyond Good Times and Bad Times
After almost a century of limited efficacy of cancer immunotherapy,1 the breakthrough happened in 2012 with the discovery of immune checkpoint inhibitors,2,3 leading to the 2018 Nobel Prize in Physiology or Medicine for James P. Allison and Tasuku Honjo. Yet about 40% of patients on immune...
Aggressive Supportive Treatment for COVID-19 May Be Needed in Patients With Hematologic Cancers
New research underscores the need for aggressive support of patients hospitalized with blood cancer and COVID-19, according to data presented at the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition. Two studies of one of the largest data sets of patients with blood cancer...
Metastatic Melanoma: Improved Overall Survival Reported With Immunotherapy Infusions Given Earlier in the Day
In a single-institution study reported in The Lancet Oncology, David C. Qian, MD, PhD, and Zachary S. Buchwald, MD, PhD, of Winship Cancer Institute of Emory University, Atlanta, and colleagues found that patients with metastatic melanoma who received at least 20% of immune checkpoint inhibitor...
Expert Point of View: Joseph Mikhael, MD
The ASCO Post asked Joseph Mikhael, MD, Chief Medical Officer of the International Myeloma Foundation and Professor in the Applied Cancer Research and Drug Discovery Division at the Translational Genomics Research Institute (an affiliate of City of Hope Cancer Center), to comment on the GMMG-HD7...
Expert Point of View: Laurie H. Sehn, MD, MPH
Press conference moderator, Laurie H. Sehn, MD, MPH, of the University of British Columbia, Vancouver, Canada, noted, that her center participated in the single-arm trial of mosunetuzumab. “We witnessed first-hand the tremendous capacity bispecific antibodies have to make a real difference in...
Mosunetuzumab Meets Primary Endpoint of Phase II Trial in Relapsed or Refractory Follicular Lymphoma
The bispecific antibody mosunetuzumab achieved deep and durable remissions as monotherapy in patients with relapsed or refractory follicular lymphoma, according to the results of a pivotal phase II trial presented at the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition.1 In ...
Expert Point of View: Jane N. Winter, MD and Christopher R. Flowers, MD, MS
Jane N. Winter, MD, Professor of Medicine at Northwestern University’s Feinberg School of Medicine and the 2022 President of the American Society of Hematology (ASH), and Christopher R. Flowers, MD, MS, Chair of the Department of Lymphoma/Myeloma at The University of Texas MD Anderson Cancer...
POLARIX: Addition of Polatuzumab Vedotin-piiq to Standard of Care Significantly Reduces Progression of Diffuse Large B-Cell Lymphoma
As a first-line treatment of inter-mediate- or high-risk diffuse large B-cell lymphoma, the addition of the antibody-drug conjugate polatuzumab vedotin-piiq to standard-of-care therapy resulted in a 27% reduction in the relative risk of disease progression, relapse, or death, with a similar safety...
Lisocabtagene Maraleucel Improves Outcomes in Relapsed or Refractory Large B-Cell Lymphoma
Chimeric antigen receptor (CAR) T-cell therapy with lisocabtagene maraleucel could prove to be the new standard-of-care treatment for patients with relapsed or refractory large B-cell lymphoma in the second-line setting, according to data presented at the 2021 American Society of Hematology (ASH)...
